Biotech Breakthroughs: Rare Diseases and AI
Kilder
- BioSpace: Relay doubles the bar, outpacing Novartis with a 60% response in rare disease - BioSpace
- Bioworld: Relay’s zovegalisib hits in phase II vascular anomalies trial - BioWorld News
- STAT: How AI helped treat a newborn’s ultra rare disease. ‘It was almost like a light switch.’ - statnews.com
- Labiotech: RAS inhibition enters its second wave - Labiotech.eu
- Bioworld: Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal - BioWorld News
- Bioworld: Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal - BioWorld News
- Fierce Biotech: ‘Flaws are being scaled, not solved’ by AI in trials: report - Fierce Biotech
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.